Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has shared an update.
Proteomics International Laboratories Ltd announced the formal retirement of founder and Managing Director Dr Richard Lipscombe from its board of directors, effective 23 February 2026, after 25 years of leadership. His departure marks the end of a tenure in which he was credited with establishing the company as a global leader in precision diagnostics, signalling a significant leadership transition that may shape the company’s next phase of strategic development.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.38 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, a subsidiary and trading name of PILL, is a Perth-based medical technology company focused on precision diagnostics and bio-analytical services. The company specialises in proteomics, the large-scale study of protein structure and function, aiming to develop innovative tools that improve disease treatment and patient outcomes.
Average Trading Volume: 593,363
Technical Sentiment Signal: Sell
Current Market Cap: A$62.77M
Find detailed analytics on PIQ stock on TipRanks’ Stock Analysis page.